# A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

> **NCT00504270** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 66 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** RG3421 120mg
- **DRUG:** RG3421 20mg

## Key facts

- **NCT ID:** NCT00504270
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504270, "A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00504270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*